# Allegria Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allegria-therapeutics

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: https://allegriatx.com/
- Total disclosed funding: $8.6M
- Latest round: Seed (Dec 3, 2025)
- Investors on record: 4

## About

Founded in 2023 and based in Switzerland, by Co-founder and CEO Maria Van Dongen, Allegria Therapeutics operates as a biotechnology research company that develops biopharmaceuticals for treating allergies and mast cell-mediated diseases. In December 2025, Allegria Therapeutics AG raised USD 5.1 million in seed funding led by ALK-Abello, with participation from HighLight Capital, Lichtsteiner Foundation and Forty51 Ventures The round was part of a larger USD 8.6 million seed round. The firm develops and offers proprietary therapeutic approaches for mast cell-mediated diseases. Mast cells play a crucial role in allergy and inflammatory conditions. The company generates revenue from providing biotech research services and engaging in R&D collaborations focused on mast cell diseases. The company will use the December 2025 funding to advance its Physical AI platform, automate drug discovery workflows, and integrate robotics and AI systems for continuous learning and large-scale experiments.

## Funding rounds

- Seed, Dec 3, 2025, $5.1M — ALK-Abello, HighLight Capital, Lichtsteiner Foundation, Forty51 Ventures
- Seed, May 6, 2024, $3.5M — Forty51 Ventures

## Investors

- Forty51 Ventures (https://capitalatlas.ai/funds/forty51-ventures) — Seed
- ALK-Abello — Seed
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Seed
- Lichtsteiner Foundation — Seed